Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ainos, Inc. (NASDAQ: AIMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Texas corporation with shares listed on the Nasdaq Stock Market, Ainos submits periodic reports, proxy statements, and current reports that document its financial condition, governance decisions, and material agreements.
For investors tracking Ainos’ transition into an AI-powered digital olfaction and SmellTech company, Form 10-K annual reports and Form 10-Q quarterly reports are key sources for detailed discussions of the AI Nose platform, Smell Language Model (SLM), VELDONA oral interferon program, research and development spending, and risk factors. Form 8-K current reports capture material events such as financial result announcements, entry into or amendments of product development agreements, and other significant corporate actions.
Ainos’ DEF 14A proxy statements provide insight into board elections, auditor ratification, stock award proposals, and shareholder voting outcomes, reflecting how the company structures its governance and equity incentives. Filings also identify Ainos’ state of incorporation, trading symbols (AIMD for common stock and AIMDW for warrants), and other corporate details.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly understand changes in capital structure, major contracts, or strategic direction without reading every page. Real-time updates from EDGAR ensure that new Ainos filings, including Forms 4 reporting insider transactions when available, appear promptly, while AI-generated overviews of 10-Ks and 10-Qs make complex disclosures more accessible to both experienced and newer investors.
Ainos, Inc. investor Ting Chuan Lee has amended his Schedule 13D filing to reflect new equity compensation and updated ownership. He now reports beneficial ownership of 935,707 shares of common stock, representing 10.98% of the class.
The shares are subject to a voting agreement between Lee and Ainos Inc., a Cayman Islands corporation. On April 15, 2026, the issuer granted him 570,000 fully vested restricted stock units under the Ainos, Inc. 2023 Stock Incentive Plan. He reports no other transactions in the past 60 days aside from this grant.
Ainos, Inc. investor Chun-Jung Tsai filed an amended Schedule 13D reporting beneficial ownership of 686,999 shares of common stock, representing 8.06% of the class. These shares include 330,000 fully vested restricted stock units granted under the Ainos, Inc. 2023 Stock Incentive Plan.
The shares are subject to a voting agreement between the reporting person and Ainos Inc., a Cayman Islands corporation. Tsai states no current plans for major corporate actions but may review and change this position over time. The filer reports no other transactions in the past 60 days aside from the equity grant.
Ainos Inc. (Cayman Islands) filed Amendment No. 15 to its Schedule 13D reporting beneficial ownership of 491,263 shares of Ainos, Inc. common stock, representing 5.76% of the class. These 491,263 shares are owned directly by Ainos KY.
Ainos KY also holds sole voting power over a total of 4,807,506 shares through direct ownership and Voting Agreements with several shareholders, including ASE Test, Inc. and various individuals. The filing notes recent restricted stock unit grants on April 15, 2026 to three individuals, over which Ainos KY has sole voting discretion under a 2026 Voting Agreement.
Ainos, Inc. director TSAI CHUN-JUNG received equity compensation through restricted stock units that immediately converted into common shares. On the transaction date, 330,000 RSUs were granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan and then converted into 330,000 shares of common stock at a stated price of $1.61 per share. Following these transactions, TSAI directly holds 686,999 shares of Ainos common stock. These are compensation-related awards rather than open-market purchases or sales.
Ainos, Inc. director and CEO Tsai Chun-hsien reported equity awards and a conversion on April 15, 2026. He received 300,000 RSUs that vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 300,000 shares of Common Stock. A related award entry shows these 300,000 Common shares at $1.61 per share, bringing his directly held Common Stock to 710,372 shares after the transactions. No open-market purchases or sales were reported; all activity reflects compensation-related grants and a derivative conversion.
Ainos, Inc. director Lee Ting-chuan reported equity compensation activity involving restricted stock units (RSUs) that converted into common shares. On April 15, 2026, he received 570,000 RSUs granted and vested under the Ainos, Inc. 2023 Stock Incentive Plan, which were then converted into 570,000 shares of common stock at a reported value of $1.61 per share. After these award and conversion transactions, Lee directly holds 935,707 shares of Ainos common stock. These are compensation-related acquisitions rather than open-market purchases or sales.
ASE Test, Inc., a 10% owner of Ainos, Inc., reported an open-market purchase of 6% Convertible Notes due 2027. The transaction covers 5,994 units of the note, each currently convertible into Ainos common stock at a $22.50 per share conversion price. Following this transaction, ASE Test, Inc. holds 105,868 units of the convertible note. The notes bear 6% compounded interest and have a maturity date extended to March 12, 2027 under an amended agreement.
ASE Technology Holding and subsidiary ASE Test, Inc. report beneficial ownership of 667,085 shares of Ainos, Inc. common stock, representing 8.4% of the class. This stake combines 11,777 shares held directly with shares issuable from a $2,000,000 2023 convertible note, a $9,000,000 2024 convertible note, and a warrant for 100,000 shares, all reflecting a one-for-five reverse stock split completed in June 2025. The notes bear 6% compound interest and are convertible primarily at $22.50 per share. ASE Test Taiwan has also granted Ainos KY broad voting discretion over its Ainos shares and agreed to annual transfer limits, underscoring a long-term, structured investment relationship.
Ainos, Inc. outlines its dual strategy of commercializing its AI-based scent digitization platform, AI Nose, and advancing its low-dose oral interferon program, VELDONA, while warning of ongoing losses and heavy funding needs. AI Nose targets healthcare and industrial applications, including semiconductor manufacturing, through hardware sales and subscription deployments. VELDONA has completed extensive human and animal studies and holds orphan drug designation for oral warts in HIV-seropositive patients, but none of the human or veterinary drug candidates are yet approved. The company reports minimal 2025 revenue, operating losses of about $14 million, cumulative losses above $67 million, cash of roughly $417 thousand, and emphasizes material dependence on new capital to continue operations.
Ainos, Inc. reported full-year 2025 results and highlighted early commercialization of its AI Nose platform. Revenue reached $124,157, up about 499% from 2024, with gross margin turning positive at roughly 82.9% after a prior-year gross loss.
Despite this top-line growth, Ainos posted a net loss of about $14.8 million, similar to 2024, as operating expenses were roughly $14.1 million. Cash and cash equivalents fell to about $417,353 versus $3.9 million a year earlier. After year-end the company raised NTD 90 million (approximately $2.82 million) to support operations and AI Nose deployment.
For 2026, Ainos is rolling out AI Nose in semiconductor environments, including around 200 systems for front-end wafer fabs and about 1,400 systems under a three-year $2.1 million deployment in semiconductor packaging and testing, with a potential roadmap to scale substantially if validations succeed.